ZHAN YANG: Open Payments
NPI 1508205618 · BUDA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,363 in 250 payments from 23 companies in 2025. Trend: 2023 $5,096 · 2024 $3,813 · 2025 $4,363
Food & beverage: $4,363
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 32 | $644 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $511 |
| Otsuka America Pharmaceutical, Inc. | 29 | $495 |
| Teva Pharmaceuticals USA, Inc. | 22 | $350 |
| ABBVIE INC. | 22 | $318 |
| Vanda Pharmaceuticals Inc. | 23 | $293 |
| E.R. Squibb & Sons, L.L.C. | 14 | $287 |
| Axsome Therapeutics, Inc. | 13 | $254 |
| Neurocrine BioSciences, Inc. | 18 | $228 |
| Janssen Pharmaceuticals, Inc | 15 | $217 |
Products named: CAPLYTA, REXULTI, ARISTADA, VRAYLAR, FANAPT, COBENFY, UZEDY, INGREZZA.
Industry payments across TX — which companies pay providers there.
